Adjunctive Ivermectin Mass Drug Administration for Malaria Elimination: A cluster randomized trial
伊维菌素大规模药物注射辅助消除疟疾:整群随机试验
基本信息
- 批准号:MR/S005013/1
- 负责人:
- 金额:$ 378.71万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2019
- 资助国家:英国
- 起止时间:2019 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This trial will be the first to investigate the impact of adding ivermectin (IVM) to mass drug administration (MDA) with an efficacious antimalarial (eg dihydroartemisinin-piperaquine (DP)) to reduce malaria transmission in a seasonal low-transmission setting. Additive IVM MDA will be compared to DP-only MDA (with treatment daily for three days during the three months of peak malaria transmission (July-September)) in combination with standard programmatic interventions for malaria control (long-lasting insecticidal nets (LLIN) and intermittent preventative treatment in pregnancy (IPTp)) in a cluster-randomized community-based trial. Primary outcome measures will be population-based Plasmodium falciparum (malaria infection) prevalence (estimated using ultra-sensitive PCR tests) and Anopheles gambiae (malaria vector) survival (measured using parity estimated by dissection of Anopheles ovaries). Data on MDA coverage, acceptability and feasibility of the intervention and a cost-effectiveness analysis will be included. We have established field infrastructure on the Bijagós Archipelago (including trained field entomologists and field laboratory technicians) and have detailed recent baseline data on the burden of disease caused by malaria and other neglected tropical diseases (NTDs) and vector populations on the islands. This 'natural laboratory' island setting provides an unparalleled opportunity to understand transmission and its interruption using a combined MDA strategy through investigating the impact of imported infections (through an expanded community-based CDSAT (case detection screen and treat) intervention which we will include in both arms), using serological (immune) markers in the blood to define transmission dynamics and estimate entomological inoculation rate (EIR) and monitoring the effect of IVM MDA on confined vector populations over time.
这项试验将是第一个研究在大规模药物给药(MDA)中加入伊维菌素(IVM)与有效抗疟药(如双氢青蒿素-哌喹(DP))以减少季节性低传播环境中疟疾传播的影响的试验。将在一项随机分组的社区试验中,将添加剂IVM MDA与仅DP MDA(在疟疾传播高峰期(7月至9月)的三个月内每天治疗三天)结合疟疾控制标准方案干预措施(长效杀虫蚊帐(LLIN)和妊娠期间歇性预防性治疗(IPT))进行比较。主要结果指标将是基于人群的恶性疟原虫(疟疾感染)流行率(使用超灵敏PCR检测估计)和冈比亚按蚊(疟疾病媒)存活率(使用解剖按蚊卵巢估计的产次测量)。将包括关于MDA覆盖率、干预措施的可接受性和可行性以及成本效益分析的数据。我们在比热戈斯群岛建立了实地基础设施(包括经过培训的实地昆虫学家和实地实验室技术人员),并掌握了关于疟疾和其他被忽视的热带疾病造成的疾病负担以及岛上病媒种群的详细最新基线数据。这种“天然实验室”岛屿环境提供了一个无与伦比的机会,通过调查输入性感染的影响,使用MDA组合策略了解传播及其中断(通过扩大的社区CDSAT(病例检测、筛查和治疗)干预,我们将在两组中纳入该干预),使用血液中的血清学(免疫)标记来确定传播动力学并估计昆虫接种率以及监测IVM MDA随时间推移对封闭病媒种群的影响。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A survey of knowledge, attitudes and practices regarding malaria and bed nets on Bubaque Island, Guinea-Bissau.
- DOI:10.1186/s12936-020-03469-1
- 发表时间:2020-11-17
- 期刊:
- 影响因子:3
- 作者:Hutchins H;Power G;Ant T;Teixeira da Silva E;Goncalves A;Rodrigues A;Logan J;Mabey D;Last A
- 通讯作者:Last A
Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.
辅助性伊维菌素大量药物给药的簇随机安慰剂对照试验的方案,该试验是对几内亚 - 比索的Bijagós群岛控制的疟疾控制:MATAMAL试验。
- DOI:10.1136/bmjopen-2023-072347
- 发表时间:2023-07-07
- 期刊:
- 影响因子:2.9
- 作者:Hutchins, Harry;Bradley, John;Pretorius, Elizabeth;da Silva, Eunice Teixeira;Vasileva, Hristina;Jones, Robert T.;Ndiath, Mamadou Ousmane;Soumare, Harouna Dit Massire;Mabey, David;Nante, Ernesto Jose;Martins, Cesario;Logan, James G.;Slater, Hannah;Drakeley, Chris;D'Alessandro, Umberto;Rodrigues, Amabelia;Last, Anna R.
- 通讯作者:Last, Anna R.
A survey of Anopheles species composition and insecticide resistance on the island of Bubaque, Bijagos Archipelago, Guinea-Bissau
- DOI:10.1186/s12936-020-3115-1
- 发表时间:2020-01-15
- 期刊:
- 影响因子:3
- 作者:Ant, Thomas;Foley, Erin;Logan, James G.
- 通讯作者:Logan, James G.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna Last其他文献
In-silico classi�cation and antigen library expression of Plasmodium falciparum STEVOR hypervariable infected erythrocyte surface-expressed multivariant protein family
恶性疟原虫 STEVOR 高变感染红细胞表面表达的多变蛋白家族的计算机分类和抗原库表达
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
Hristina Vasileva;Anna Last - 通讯作者:
Anna Last
Reduced-cost Chlamydia trachomatis-specific multiplex real-time 3 PCR diagnostic assay evaluated for ocular swabs and use by 4 trachoma research programmes
降低成本的沙眼衣原体特异性多重实时 3 PCR 诊断测定法对眼拭子进行了评估并被 4 个沙眼研究项目使用
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
R. Butcher;J. Houghton;Tamsyn Derrick;Athumani M. Ramadhani;Beatriz;Herrera;Anna Last;P. Massae;M. Burton;M. Holland;C. Roberts - 通讯作者:
C. Roberts
A survey of indoor and outdoor Anopheles density, species composition and circumsporozoite rate of malaria vectors on the Bijagós Archipelago, Guinea-Bissau
- DOI:
10.1186/s12936-025-05372-z - 发表时间:
2025-06-19 - 期刊:
- 影响因子:3.000
- 作者:
Elizabeth Pretorius;Robert T. Jones;Harry Hutchins;Eunice Teixeira Da Silva;Sainey Ceesay;Mamadou Ousmane Ndiath;Umberto d’Alessandro;Amabelia Rodrigues;James G. Logan;Anna Last - 通讯作者:
Anna Last
Broadening the Range of Use Cases for Ivermectin – a Review of the 2 Evidence 3
扩大伊维菌素的使用案例范围 - 2 个证据的回顾 3
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
C. Kositz;J. Bradley;Harry Hutchins;Anna Last;U. d’Alessandro;M. Marks - 通讯作者:
M. Marks
A practical critique of antifungal treatment guidelines for haemato-oncologists
血液肿瘤学家抗真菌治疗指南的实用批评
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:6.5
- 作者:
S. Agrawal;B. Jones;R. Barnes;C. Kibbler;M. Millen;M. Ashcroft;Sarjana Jain;Anna Last;David Lewis;T. Lewis;Mitul Patel;A. Pagliuca - 通讯作者:
A. Pagliuca
Anna Last的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Population genomics of ivermectin drug resistance in parasitic nematodes of livestock
家畜寄生线虫伊维菌素耐药性的群体基因组学
- 批准号:
RGPIN-2021-02489 - 财政年份:2022
- 资助金额:
$ 378.71万 - 项目类别:
Discovery Grants Program - Individual
Analysis of tumor suppression mechanism by antiparasitic drug Ivermectin targeting cancer stem cells
抗寄生虫药伊维菌素靶向肿瘤干细胞抑制肿瘤机制分析
- 批准号:
22K07311 - 财政年份:2022
- 资助金额:
$ 378.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Population genomics of ivermectin drug resistance in parasitic nematodes of livestock
家畜寄生线虫伊维菌素耐药性的群体基因组学
- 批准号:
RGPIN-2021-02489 - 财政年份:2021
- 资助金额:
$ 378.71万 - 项目类别:
Discovery Grants Program - Individual
Ivermectin Treatment of Livestock for Malaria Control on Sumba Island
松巴岛用伊维菌素治疗牲畜以控制疟疾
- 批准号:
MR/V004670/1 - 财政年份:2021
- 资助金额:
$ 378.71万 - 项目类别:
Research Grant
Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage
伊维菌素抗疟治疗恶性疟原虫肝期的评价
- 批准号:
10001705 - 财政年份:2020
- 资助金额:
$ 378.71万 - 项目类别:
Exploring the effect of non-target ivermectin exposure to dung beetles (Coleoptera: Scarabaeoidea)
探索非目标伊维菌素暴露对粪甲虫(鞘翅目:金龟子科)的影响
- 批准号:
532422-2019 - 财政年份:2020
- 资助金额:
$ 378.71万 - 项目类别:
Postdoctoral Fellowships
Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage
伊维菌素抗疟治疗恶性疟原虫肝期的评价
- 批准号:
10170295 - 财政年份:2020
- 资助金额:
$ 378.71万 - 项目类别:
Exploring the effect of non-target ivermectin exposure to dung beetles (Coleoptera: Scarabaeoidea)
探索非目标伊维菌素暴露对粪甲虫(鞘翅目:金龟子科)的影响
- 批准号:
532422-2019 - 财政年份:2019
- 资助金额:
$ 378.71万 - 项目类别:
Postdoctoral Fellowships
The effect of ivermectin residues on insect-mediated dung decomposition
伊维菌素残留对昆虫介导的粪便分解的影响
- 批准号:
525430-2018 - 财政年份:2018
- 资助金额:
$ 378.71万 - 项目类别:
University Undergraduate Student Research Awards
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria
重复伊维菌素大规模药物管理用于疟疾控制 II (RIMDAMAL II):疟疾综合控制的双盲整群随机试验
- 批准号:
9754784 - 财政年份:2018
- 资助金额:
$ 378.71万 - 项目类别: